# OnCo record paper-le-mmr-deficiency-pd1-nejm-2015 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-le-mmr-deficiency-pd1-nejm-2015/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-le-mmr-deficiency-pd1-nejm-2015" ;
  schema:name "Le 2015: PD-1 blockade works in tumours with mismatch-repair deficiency, whatever the organ"@en ;
  schema:description "Pembrolizumab shrank tumours in 40% of colorectal and 71% of other cancers with faulty DNA mismatch repair, but in none with intact repair, tying immunotherapy response to mutation burden."@en ;
  schema:url <https://onco.cc/key-papers/paper-le-mmr-deficiency-pd1-nejm-2015/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1500596>, <https://clinicaltrials.gov/study/NCT01876511>, <https://pubmed.ncbi.nlm.nih.gov/26028255/>, <https://europepmc.org/article/MED/26028255> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1500596> ;
  schema:datePublished "2015"^^xsd:gYear ;
  schema:author "Le DT, Uram JN, Wang H, et al." ;
  onco:related <https://onco.cc/key-papers/paper-le-mmr-deficiency-science-2017/>, <https://onco.cc/key-papers/paper-cercek-dostarlimab-rectal-nejm-2022/>, <https://onco.cc/biomarkers/msi-high/>, <https://onco.cc/biomarkers/dmmr-ihc/>, <https://onco.cc/biomarkers/tmb-high/>, <https://onco.cc/key-papers/paper-keynote-177-nejm-2020/> ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/msi-high-colorectal/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/msi-mmr-testing/>, <https://onco.cc/technologies/wes-wgs/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/mmr/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:institutions <https://onco.cc/institutions/johns-hopkins/> ;
  onco:pathways <https://onco.cc/pathways/mismatch-repair-msi/>, <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/cancer-immunity-cycle/> ;
  onco:terms <https://onco.cc/terms/msi/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/neoantigen/>, <https://onco.cc/terms/tumour-agnostic/>, <https://onco.cc/terms/mss-pmmr/>, <https://onco.cc/targets/mmr/> ;
  onco:people <https://onco.cc/people/dung-le/>, <https://onco.cc/people/luis-diaz/>, <https://onco.cc/people/drew-pardoll/>, <https://onco.cc/people/bert-vogelstein/>, <https://onco.cc/people/kenneth-kinzler/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-immunotherapy-response/> ;
  onco:journals <https://onco.cc/journals/nejm/> .
